• Je něco špatně v tomto záznamu ?

RAD51 recruitment but not replication fork stability associates with PARP inhibitor response in ovarian cancer patient-derived xenograft models

F. Talens, VON. Teixeira, YP. Kok, M. Chen, EH. Rosenberg, R. Debipersad, EW. Duiker, N. van den Tempel, M. Janatova, P. Zemankova, PM. Nederlof, GBA. Wisman, Z. Kleibl, S. de Jong, MATM. van Vugt

. 2024 ; 6 (4) : zcae044. [pub] 20241128

Status neindexováno Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25002029

Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPis) are currently used to treat BRCA1/2 mutant cancers. Although PARPi sensitivity has been attributed to homologous recombination (HR) defects, other roles of HR factors have also been linked to response to PARPi, including replication fork protection. In this study, we investigated PARPi sensitivity in ovarian cancer patient-derived xenograft (PDX) models in relation to HR proficiency and replication fork protection. Analysis of BRCA1/2 status showed that in our cohort of 31 ovarian cancer PDX models 22.6% harbored a BRCA1/2 alteration (7/31), and 48.3% (15/31) were genomically unstable as measured by copy number alteration analysis. In vivo, PARPi olaparib response was measured in 15 selected PDX models. Functional assessment of HR using ex vivo irradiation-induced RAD51 foci formation identified all olaparib-sensitive PDX models, including four models without BRCA1/2 alterations. In contrast, replication fork protection or replication speed in ex vivo tumor tissue did not correlate with olaparib response. Targeted panel sequencing in olaparib-sensitive models lacking BRCA1/2 alterations revealed a MUS81 variant as a possible mechanism underlying PARPi sensitivity. Combined, we show that ex vivo RAD51 analysis effectively predicts in vivo olaparib response and revealed a subset of PARPi-sensitive, HR-deficient ovarian cancer PDX models, lacking a BRCA1/2 alteration.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25002029
003      
CZ-PrNML
005      
20250123101948.0
007      
ta
008      
250117s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/narcan/zcae044 $2 doi
035    __
$a (PubMed)39611179
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Talens, Francien $u Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713GZ Groningen, the Netherlands
245    10
$a RAD51 recruitment but not replication fork stability associates with PARP inhibitor response in ovarian cancer patient-derived xenograft models / $c F. Talens, VON. Teixeira, YP. Kok, M. Chen, EH. Rosenberg, R. Debipersad, EW. Duiker, N. van den Tempel, M. Janatova, P. Zemankova, PM. Nederlof, GBA. Wisman, Z. Kleibl, S. de Jong, MATM. van Vugt
520    9_
$a Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPis) are currently used to treat BRCA1/2 mutant cancers. Although PARPi sensitivity has been attributed to homologous recombination (HR) defects, other roles of HR factors have also been linked to response to PARPi, including replication fork protection. In this study, we investigated PARPi sensitivity in ovarian cancer patient-derived xenograft (PDX) models in relation to HR proficiency and replication fork protection. Analysis of BRCA1/2 status showed that in our cohort of 31 ovarian cancer PDX models 22.6% harbored a BRCA1/2 alteration (7/31), and 48.3% (15/31) were genomically unstable as measured by copy number alteration analysis. In vivo, PARPi olaparib response was measured in 15 selected PDX models. Functional assessment of HR using ex vivo irradiation-induced RAD51 foci formation identified all olaparib-sensitive PDX models, including four models without BRCA1/2 alterations. In contrast, replication fork protection or replication speed in ex vivo tumor tissue did not correlate with olaparib response. Targeted panel sequencing in olaparib-sensitive models lacking BRCA1/2 alterations revealed a MUS81 variant as a possible mechanism underlying PARPi sensitivity. Combined, we show that ex vivo RAD51 analysis effectively predicts in vivo olaparib response and revealed a subset of PARPi-sensitive, HR-deficient ovarian cancer PDX models, lacking a BRCA1/2 alteration.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Teixeira, Vivian Oliviera Nunes $u Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713GZ Groningen, the Netherlands
700    1_
$a Kok, Yannick P $u Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713GZ Groningen, the Netherlands
700    1_
$a Chen, Mengting $u Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713GZ Groningen, the Netherlands
700    1_
$a Rosenberg, Efraim H $u Department of Pathology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, the Netherlands
700    1_
$a Debipersad, Rashmie $u Department of Pathology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, the Netherlands
700    1_
$a Duiker, Evelien W $u Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713GZ Groningen, the Netherlands
700    1_
$a van den Tempel, Nathalie $u Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713GZ Groningen, the Netherlands
700    1_
$a Janatova, Marketa $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Katerinska 32, 128 00 Prague, Czech Republic
700    1_
$a Zemankova, Petra $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Katerinska 32, 128 00 Prague, Czech Republic $u Department of Pathophysiology, First Faculty of Medicine, Charles University, U Nemocnice 5, 128 00 Prague, Czech Republic
700    1_
$a Nederlof, Petra M $u Department of Pathology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, the Netherlands
700    1_
$a Wisman, G Bea A $u Department of Gynecology and Obstetrics, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713GZ Groningen, the Netherlands
700    1_
$a Kleibl, Zdenek $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Katerinska 32, 128 00 Prague, Czech Republic $u Department of Pathophysiology, First Faculty of Medicine, Charles University, U Nemocnice 5, 128 00 Prague, Czech Republic
700    1_
$a de Jong, Steven $u Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713GZ Groningen, the Netherlands
700    1_
$a van Vugt, Marcel A T M $u Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713GZ Groningen, the Netherlands $1 https://orcid.org/0000000232024678
773    0_
$w MED00209101 $t NAR cancer $x 2632-8674 $g Roč. 6, č. 4 (2024), s. zcae044
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39611179 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250117 $b ABA008
991    __
$a 20250123101942 $b ABA008
999    __
$a ok $b bmc $g 2254448 $s 1238032
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2024 $b 6 $c 4 $d zcae044 $e 20241128 $i 2632-8674 $m NAR cancer $n NAR Cancer $x MED00209101
LZP    __
$a Pubmed-20250117

Najít záznam

Citační ukazatele

Možnosti archivace